title: [The histological lesions of chronic hepatitis C as predicting factors of sustained response to the treatment with interferon].
abstract: BACKGROUND
  Although many studies have been implemented in order to determine the pre-treatment factors that can predict patients' response to interferon (IFN) therapy, it is not yet clear whether characteristic histologic abnormalities in chronic hepatitis C can predict such response.
  
  
  OBJECTIVE
  The aim of this study were to evaluate, in patients with chronic hepatitis C, (i) the predictive value of histologic lesions for the sustained response to IFN therapy (ii) other pre-treatment (epidemiological and analytical) factors known to be predictive of response.
  
  
  METHODS
  Sustained response was retrospectively evaluated in two hundred one patients who had been treated with IFN for at least 3 months in four different hospitals from Castilla y León. The following histological parameters were studied as predictors of response: histological diagnosis, Knodell index, grading and stage, characteristic histologic lesions of HCV infection. Epidemiological and analytical parameters were also evaluated.
  
  
  RESULTS
  The rate of patient's sustained response to IFN treatment was 16%. None of the histological parameters was useful to predict this response. By univariate analysis, age, disease evolution time, mode of viral transmission, GGT, ferritin and viral genotype were associated with a sustained response. The most powerful, and only independent predictive factor, however, was the genotype (the response odds ratio was 8.6).
  
  
  CONCLUSIONS
  Histological parameters do not predict the response to IFN treatment. Other factors (mainly the viral genotype) are associated with a higher response percentage, although no one is useful to decide which patients are going to respond.
authors.affiliation: Sección de Aparato Digestivo, Hospital General Yagüe, Burgos.
authors.forename: E G
authors.initials: EG
authors.lastname: Gento Peña
authors.forename: A
authors.initials: A
authors.lastname: López Morante
authors.forename: J
authors.initials: J
authors.lastname: Cordero Guevara
authors.forename: C
authors.initials: C
authors.lastname: Echevarría Iturbe
authors.forename: J L
authors.initials: JL
authors.lastname: Martín Lorente
authors.forename: J L
authors.initials: JL
authors.lastname: Olcoz Goñi
authors.forename: F
authors.initials: F
authors.lastname: González San Martín
authors.forename: A
authors.initials: A
authors.lastname: Caro-Patón Gómez
authors.forename: F
authors.initials: F
authors.lastname: Jorquera Plaza
authors.forename: R
authors.initials: R
authors.lastname: Velicia Llames
authors.forename: F
authors.initials: F
authors.lastname: Sáez-Royuela
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011237:Predictive Value of Tests; D011994:Recombinant Proteins; D012189:Retrospective Studies
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
vernacular_title: Las lesiones anátomo-patológicas de la hepatitis crónica C como factores predictivos de respuesta mantenida al tratamiento con interferón.